Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amdizalisib - HUTCHMED

Next Previous
Drug Profile

Amdizalisib - HUTCHMED

Alternative Names: Andilise - HUTCHMED; HMPL-689

Latest Information Update: 28 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hutchison MediPharma
  • Developer HUTCHMED
  • Class Amines; Antineoplastics; Chlorinated hydrocarbons; Imidazoles; Nitriles; Pyridazines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Follicular lymphoma; Lymphoma; Marginal zone B-cell lymphoma
  • Phase I Non-Hodgkin's lymphoma
  • No development reported Haematological malignancies

Most Recent Events

  • 02 Aug 2023 Hutchison MediPharma completes a first-in-human phase I/Ib trial in Non-Hodgkin's lymphoma (Second-line therapy or greater, Monotherapy) in China (PO, Capsule) (NCT03128164)
  • 09 Jun 2023 Updated efficacy and adverse events data from a phase Ib trial in Non-Hodgkin's lymphoma released by HUTCHMED
  • 27 Feb 2023 Hutchmed announces intention to submit MAA to National Medical Products Administration (NMPA) for Follicular Lymphoma (relapsed/refractory)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top